Section Arrow
Quote
WINT.NASDAQ
- Windtree Therapeutics Inc.
(Financial Status)
Quotes are at least 15-min delayed:2025/07/21 06:43 EDT
Pre Market
Last
 1.21
+0.02 (+1.68%)
Bid
1.21
Ask
1.22
High 1.33 
Low 1.19 
Volume 931797 
Regular Hours
Last
 1.19
+0.14 (+13.33%)
Day High 
1.35 
Prev. Close
1.05 
1-M High
1.86 
Volume 
19.50M 
Bid
1.21
Ask
1.22
Day Low
1.09 
Open
1.27 
1-M Low
0.36 
Market Cap 
9.71M 
Currency USD 
P/E 0.84 
%Yield -- 
10-SMA 0.81 
20-SMA 0.66 
50-SMA 0.72 
52-W High 737.435 
52-W Low 0.1046 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-6,321.50/-2.16
Enterprise Value
10.36M
Balance Sheet
Book Value Per Share
0.89
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 2 -0.28 -12.28%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13.13 -0.945 -6.71%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0475 -0.0002 -0.42%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.22 +0.38 +6.51%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.06 +0.14 +2.36%
Quotes are at least 15-min delayed：2025/07/21 06:43 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.